GlassScriptPhysician profile
Matthew Jon Shore
NPI 1497803514
$56,934.57
in general payments reported to CMS, 2019-2025
69 companies · $5,125 in 2025
The $5,125 reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,348 · 2020: $3,949 · 2021: $12K · 2022: $12K · 2023: $9,993 · 2024: $4,608 · 2025: $5,125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,064 · Consulting Fee: $274 · Travel and Lodging: $87.95 · Education: $41.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,258.85 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,063.75 |
| Consulting Fee | $274.00 |
| Travel and Lodging | $87.95 |
| Education | $41.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $10,519.34 | 2019-2025 | Otezla, Krystexxa, Otezla |
| Idorsia Pharmaceuticals US INC | $6,474.34 | 2023 | Quviviq |
| Abbvie INC. | $6,456.44 | 2019-2025 | Qulipta, Vraylar, Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $5,691.97 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Allergan, INC. | $3,923.95 | 2019-2020 | |
| Novo Nordisk INC | $2,891.06 | 2019-2025 | Ozempic |
| Janssen Pharmaceuticals, INC | $1,874.22 | 2019-2024 | Xarelto |
| Sanofi-Aventis U.S. LLC | $1,851.16 | 2019-2023 | |
| Pfizer INC. | $1,238.78 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,187.48 | 2019-2025 | Trintellix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,117.50 | 2019-2024 | Xifaxan, Trulance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,028.88 | 2019-2025 | Synjardy, Jardiance, Jascayd |
| Genentech USA, INC. | $990.00 | 2022 | |
| Esperion Therapeutics, INC. | $786.36 | 2020-2023 | Nexletol |
| Glaxosmithkline, LLC. | $730.82 | 2019-2025 | Arexvy, Shingrix, Fluarix Quadrivalent |
Show all 69 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Shore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.